3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Carcinoma, Non-Small-Cell Lung
128
Melanoma
65
Squamous Cell Carcinoma of Head and Neck
64
Parkinson Disease 4, Autosomal Dominant Lewy Body
52
Lung Neoplasms
51
Triple Negative Breast Neoplasms
47
Neoplasm Metastasis
45
Breast Neoplasms
42
Neoplasms
39
Colorectal Neoplasms
34
Carcinoma, Renal Cell
30
Head and Neck Neoplasms
29
Endometrial Neoplasms
28
Ovarian Neoplasms
27
Carcinoma, Transitional Cell
22
Urinary Bladder Neoplasms
21
Stomach Neoplasms
17
Carcinoma
16
Pancreatic Neoplasms
15
Uterine Cervical Neoplasms
14
Esophageal Neoplasms
13
Brain Neoplasms
13
Recurrence
12
Sarcoma
11
Hodgkin Disease
11
Carcinoma, Squamous Cell
11
Carcinoma, Hepatocellular
11
Cholangiocarcinoma
10
Skin Neoplasms
9
Esophageal Squamous Cell Carcinoma
9
Interventions
Rituximab
9
venetoclax
7
ibrutinib
7
Cyclophosphamide
7
Mycophenolic Acid
5
fludarabine phosphate
4
Whole-Body Irradiation
4
Sirolimus
4
zanubrutinib
3
pirtobrutinib
3
Peripheral Blood Stem Cell Transplantation
3
Dexamethasone
3
Cyclosporine
3
ixazomib
2
fludarabine
2
carfilzomib
2
acalabrutinib
2
Tacrolimus
2
Melphalan
2
Etoposide
2
Cyclosporins
2
Calcium Dobesilate
2
CT-P10
2
Busulfan
2
Bendamustine Hydrochloride
2
talquetamab
1
pembrolizumab
1
loncastuximab tesirine
1
brexucabtagene autoleucel
1
Vincristine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Waldenstrom Macroglobulinemia
×
pembrolizumab
×
90 days
×
Clear all
NCT02362035
2026-05-13
KEYNOTE145
Acerta Pharma BV
Phase 1/2
Completed
161 enrolled
29 charts